About us

At Crossfire Oncology we have a deep understanding of kinases that play a pivotal role in many cellular processes, including proliferation, survival, migration, and differentiation.

Based on our proprietary EPriL (Energetically Privileged Ligands) chemistry we have developed a unique platform of kinase inhibitors, degraders, and degrader antibody conjugates (DACs). This allows us to select and develop the most suitable approach for each target kinase to ensure an optimal therapeutic effect.

The Crossfire team has decades of experience in medicinal chemistry and was closely involved in the design of clinically and commercially successful drugs. BAL0891, a potent TTK/PLK1 inhibitor, was fully designed in house and is currently in clinical development.

Crossfire Oncology
Crossfire Oncology

The crossfire team

Rogier Buijsman

Rogier Buijsman

CEO

Martine Prinsen

Martine Prinsen

Senior Scientist Biology

Jos de Man

Jos de Man

Head of Chemistry

Freek van Cauter

Freek van Cauter

Senior Scientist Chemistry

Jan Gerard Sterrenburg

Jan Gerard Sterrenburg

Senior Scientist Chemistry

Joeri de Wit

Joeri de Wit

Senior Scientist Chemistry

Sander van Gemert

Sander van Gemert

Scientist Chemistry & Crystallography

Michelle Muller

Michelle Muller

Scientist Biology

Diep Vu

Diep Vu

Senior Scientist Analytics & Crystallography

Winfired Mulder

Winfried Mulder

Senior Scientist Biology

Yvonne van Mill

Yvonne van Mil

Scientist Biology

Erik Ensing

Erik Ensing

CBO

Joost Uitdehaag

Joost Uitdehaag

Head of Biology

Milan Hoffmann

Scientist